Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression (SAINT-TRD)

      Background: Intermittent theta-burst stimulation (iTBS) is an FDA-approved treatment for treatment-resistant depression (TRD). Typical courses involve daily stimulation sessions for six weeks and average response rates are around 50%. Several studies have demonstrated the safety and potential enhanced efficacy of accelerated theta-burst stimulation. Higher pre-treatment anti-correlation between the stimulated region of the left dorsolateral prefrontal cortex (L-DLPFC) and subcallosal cingulate cortex (SCC) has been associated with better clinical outcome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'